Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinai ImmunotherapeuticsFRA:2F5 -0.94%20 Days Payable is 33.55 as of Mar. 2026, which is 61% below its 10-year median of 85.18. GuruFocus rates FRA:2F5 with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Scinai Immunotherapeutics ranks worse than 59.54% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2F5 vs ABPO, ISCO, ZVSA: Days Payable Comparison
For the Biotechnology subindustry, Scinai Immunotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinai Immunotherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Scinai Immunotherapeutics's Days Payable falls into.
Scinai Immunotherapeutics Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Scinai Immunotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics (FRA:2F5) has a Days Payable of 33.55 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scinai Immunotherapeutics and its competitors. This is 61% below median its historical median of 85.18. Over the past decade, Scinai Immunotherapeutics' Days Payable has ranged from 36.06 to 134.30. According to the industry distribution chart, Scinai Immunotherapeutics ranks #418 out of 702 companies in the Biotechnology industry, placing it in the top 59.5%.
Is Scinai Immunotherapeutics' Days Payable too high?
Scinai Immunotherapeutics' current Days Payable of 33.55 is 61% below median its 10-year median of 85.18. Over the past 10 years, this metric has ranged from a low of 36.06 to a high of 134.30. The Biotechnology industry median Days Payable is 113.10. Scinai Immunotherapeutics' value of 33.55 is 70.3% below this industry median. Based on the distribution chart, Scinai Immunotherapeutics ranks #418 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scinai Immunotherapeutics' Days Payable compare to ABPO and ISCO?
According to the Biotechnology industry distribution chart, Scinai Immunotherapeutics ranks #418 out of 702 companies for Days Payable. This places Scinai Immunotherapeutics in the lower half of its industry. The industry median Days Payable is 113.10. Scinai Immunotherapeutics' value of 33.55 is 70.3% below this benchmark. Historically, Scinai Immunotherapeutics' own Days Payable has ranged from 36.06 to 134.30 over the past decade. While the company's 10-year median is 85.18 vs. the industry median of 113.10, Scinai Immunotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinai Immunotherapeutics's current Days Payable of 33.55 is 70.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scinai Immunotherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinai Immunotherapeutics's current Days Payable is 33.55, which is 61% below median its own 10-year median of 85.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinai Immunotherapeutics stock overvalued right now?
Scinai Immunotherapeutics (FRA:2F5) has a current Days Payable of 33.55. The current Days Payable is 33.55, which is 61% below median its 10-year median of 85.18 and 70.3% below the Biotechnology industry median of 113.10. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Scinai Immunotherapeutics (FRA:2F5), the current Days Payable is 33.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
20GF Score
Get the complete analysis for FRA:2F5
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2F5 has been successfully added to your 
